Serum interleukin-18 and tumor necrosis factor alpha in ankylosing spondylitis

被引：0
|
作者：
Zheng, DH [1 ]
Dal, L [1 ]
Wu, YM [1 ]
Han, ZJ [1 ]
机构：
[1] Zhongshan Univ, Affiliated Hosp 2, Dept Rheumatol, Guangzhou, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：326 / +
页数：2
相关论文
共 50 条
  • [31] Anti-tumor necrosis factor alpha treatment does not influence serum levels of the markers associated with radiographic progression in ankylosing spondylitis
    Ozdemirel, Ali Erhan
    Guven, Serdar Can
    Doganci, Alper
    Surmeli, Zuhre Sari
    Ozyuvali, Ayla
    Kurt, Mehmet
    Rustemova, Diana
    Hassan, Selin
    Sayin, Ayse Peyman Yalcin
    Tutkak, Huseyin
    Ataman, Sebnem
    ARCHIVES OF RHEUMATOLOGY, 2023, 38 (01) : 148 - 155
  • [32] The association between tumor necrosis factor alpha promoter polymorphisms and ankylosing spondylitis: A meta-analysis
    Ma, Bo
    Yang, Bing
    Guo, Hainiu
    Wang, Yihong
    Zhang, Dayi
    Zhang, Yuan
    Xiao, Zhengquan
    HUMAN IMMUNOLOGY, 2013, 74 (10) : 1357 - 1362
  • [33] Treatment of uveitis and ankylosing spondylitis refractory to three tumor necrosis factor alpha inhibitors drugs with golimumab
    Chaparro Sanabria, Jeimy Andrea
    Bautista Molano, Wilson
    Valle Onate, Rafael
    REUMATOLOGIA CLINICA, 2020, 16 (01): : 64 - 65
  • [34] Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis A meta-analysis
    Ma, Zeren
    Liu, Xiaoping
    Xu, Xiaosheng
    Jiang, Jie
    Zhou, Jian
    Wang, Jia
    Chen, Dewang
    Luo, Song
    MEDICINE, 2017, 96 (25)
  • [35] Cost–benefit analysis of tumor necrosis factor inhibitors in ankylosing spondylitis
    Rachel Murphy
    Nature Clinical Practice Rheumatology, 2006, 2 (5): : 237 - 238
  • [36] Predictors of response to tumor necrosis factor-α blockers in ankylosing spondylitis
    Burgos-Vargas, R
    Rojas-Serrano, J
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (09) : 1637 - 1640
  • [37] Benefits of tumor necrosis factor inhibitors for cardiovascular disease in ankylosing spondylitis
    Huang, Jin-Xian
    Lee, Yung-Heng
    Wei, James Cheng-Chung
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 112
  • [38] Economic evaluation of tumor necrosis factor inhibitors in the treatment of ankylosing spondylitis
    Parekh, H. H.
    Kamal, K. M.
    VALUE IN HEALTH, 2007, 10 (03) : A118 - A118
  • [39] Ankylosing Spondylitis Refractory to Tumor Necrosis Factor Blockade Responds to Tocilizumab
    Cohen, Jean-David
    Ferreira, Rosanna
    Jorgensen, Christian
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (07) : 1527 - 1528
  • [40] POLYMORPHISM OF TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) AT POSITION -308 IN RELATION TO ANKYLOSING-SPONDYLITIS
    VERJANS, GMGM
    BRINKMAN, BMN
    VANDOORNIK, CEM
    KIJLSTRA, A
    VERWEIJ, CL
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 97 (01): : 45 - 47
12345